Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Morning Note to Clients Oct 4, 2010: New Milestones and Updates at AndrewNava.com

|Includes:Achillion Pharmaceuticals, Inc. (ACHN), AMGN, ENDP, GSK, OPTR, PGNX, RPRX

Below is a sample email sent out to clients of AndrewNava.com.  The email briefly lists new milestones added to AndrewNava.com as well as several new database updates, including updated financial and clinical data.

Dear Client,

Here are the latest updates at AndrewNava.com...

NEW MILESTONES:

ACHN: 28-day and 12-week phase 2 data expected in 1Q11 and 4Q11, respectively, from ACH-1625.
AMGN:
Renal/CV AdComm to discuss Aranesp TREAT Study 10/18/10.
ENDP:
Oxymorphone new formulation PDUFA Jan. 7, 2011.
HGSI:
Benlysta Arthritis AdComm 11/16/10.
OPTR:
Fidaxomicin rolling NDA filed 9/21/10 with expected approval March 21, 2011 (will request priority review).
PGNX:
Relistor subcutaneous sNDA filing expected 1H11 (chronic pain OIC), pre-filled syringe (8 and 12 mg) launch expected 1H11.
RPRX:
Type B meeting on November 8, 2010 with the FDA Division of Reproductive and Urologic Products to review Androxal Phase III pivotal trial protocols.
ZLCS:
Prednisporin (FOV1101) data expected YE10 from Sanofi-Aventis (Fovea) persistant allergic conjunctivitis study.

DATABASE UPDATES: ETRM, CXM, CLSN, PPHM, ANTH, CPRX, ACCP, VRX, BIIB, NNVC, VICL, BSDM, RIGL, ENDP, CHTP, SNSS, EBS, XOMA, DYAX, AVEO, CERS, YMI (financials), ALNY, tesetaxel, ONTY, PTN, ICO, CORX, OGX-427, APRI.


For full milestones, clinical trial data, and drug sales, please visit
http://andrewnava.com

Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and our database of clinical trial data and upcoming company milestones.

Disclosure: No positions

Disclosure: No positions

Stocks: ACHN, AMGN, ENDP, GSK, OPTR, PGNX, RPRX